The company intends to use the funds to advance ADVC001, its novel Lead-212 PSMA-targeted radioligand therapy for metastatic prostate cancer toward Phase 3 development, expand vertically integrated radiopharmaceutical platform and manufacturing infrastructure, and accelerate its growing pipeline of targeted alpha therapies

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

Level 7, Macquarie House, 167 Macquarie St,
Sydney, NSW, 2000
AU

Phone

Undisclosed

Website

advancell.com.au/

Email Address

Undisclosed

Overview

AdvanCell is a radiopharmaceutical company developing next-generation cancer treatments. AdvanCell's targeted alpha therapies are powered by a platform technology -- a world-first alpha isotope generator which addresses the greatest unmet need in targeted alpha therapy -- the reliable and scalable supply of isotope.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chairman

Bill Ferris

Chief Executive Officer

Andrew Adamovich

Chief Technical Officer

Simon Puttick

Browse more venture capital transactions:

Prev: 7/15/2026: Lyora Therapeutics venture capital transaction
Next: 7/16/2026: Silicon Microgravity venture capital transaction

Share this article

Where The Data Comes From

We record tech company VC transactions. VC transactions reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary